Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.
The present study aimed to evaluate the side-effects and efficacy of thalidomide in combination with an anthracycline-containing chemotherapy regimen in previously untreated myeloma patients. Thalidomide (400 mg/d) was combined with bolus injections of vincristine and epirubicin and oral dexamethaso...
Main Authors: | Schütt, P, Ebeling, P, Buttkereit, U, Brandhorst, D, Opalka, B, Hoiczyk, M, Flasshove, M, Hense, J, Bojko, P, Metz, K, Moritz, T, Seeber, S, Nowrousian, MR |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2005
|
Similar Items
-
Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival.
by: Schütt, P, et al.
Published: (2005) -
In vitro dendritic cell generation and lymphocyte subsets in myeloma patients: influence of thalidomide and high-dose chemotherapy treatment.
by: Schütt, P, et al.
Published: (2005) -
Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections.
by: Schütt, P, et al.
Published: (2006) -
The clinical significance of soluble human leukocyte antigen class-I, ICTP, and RANKL molecules in multiple myeloma patients.
by: Schütt, P, et al.
Published: (2008) -
Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma.
by: Nowrousian, MR, et al.
Published: (2005)